A
AIGEN Sciences
AI-driven drug discovery platform enhancing efficiency and success rates in clinical phases with minimal toxicity
About AIGEN Sciences
AIGEN Sciences Inc. operates in the pharmaceutical and biotechnology sector, focusing on AI-driven drug discovery. The company leverages its award-winning AI platform to transform traditional drug discovery processes, which are often costly and inefficient, into rapid and efficient methodologies. This approach aims to increase the success rates of drugs in clinical phases by directly discovering high-potency drugs that target cellular activity with minimal off-target effects and toxicity. AIGEN Sciences serves pharmaceutical companies and research institutions looking to enhance their drug development pipelines. The business model revolves around providing access to its AI platform and collaborating on drug development projects, generating revenue through partnerships and licensing agreements. As a spin-off from Korea University's DMIS Lab, AIGEN Sciences benefits from a strong academic foundation and expertise in computer science and bioinformatics. The company is supported by grants, such as those from the Korea Drug Development Fund (KDDF), which further bolster its research and development capabilities.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Seoul, South Korea
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 72.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Biotech and Pharma, AI Drug Discovery, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2025 | $0 | — | Hyosung Ventures | ↗ |
| EARLY VC✓Equity / VC | Oct 2024 | $8.8M | $35M | Premier Partners · Partners Investment · K2 Investment Partners · Medytox Venture Investment | — |
Growth signals
Latest recorded traffic for AIGEN Sciences is 1.9K monthly website visits, up 46.2% over the last three months. AIGEN Sciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Premier Partners
Partners Investment
K2 Investment Partners
Medytox Venture Investment
QUAD Ventures
Scale Up Partners
Hyosung Ventures
Other known investors1 additional known investor
Korea University Holdings
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AIGEN Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AIGEN Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.